Invasive fungal infections in acute leukemia

Therapeutic Advances in Hematology

Volumn 2, Issue 4, 2011, Pages 231-247

  Bhatt, Vijaya R ^a   Viola, George M ^a   Ferrajoli, Alessandra ^b  

^a STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

fungus; infection; leukemia; mold; yeast

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; DEOXYCHOLIC ACID; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; LIPID; MICAFUNGIN; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACREMONIUM; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ALOPECIA; ASPERGILLOSIS; ASPERGILLUS; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BLOOD CULTURE; BLOODSTREAM INFECTION; BRAIN DISEASE; CANDIDEMIA; CANDIDIASIS; CLADOSPORIUM; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; CRYPTOCOCCUS; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DYSPNEA; EDEMA; FEVER; FLANK PAIN; FLUSHING; FUSARIUM; GENETIC POLYMORPHISM; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; HYPOXIA; IMMUNOSUPPRESSIVE TREATMENT; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LEG PAIN; LIVER TOXICITY; LUNG LAVAGE; LUNG MYCOSIS; MULTICENTER STUDY (TOPIC); NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; PENICILLIUM; PHOTOTOXICITY; PICHIA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHODOTORULA; RIGOR; SCEDOSPORIUM; SIDE EFFECT; SYSTEMIC MYCOSIS; THORAX PAIN; TREATMENT RESPONSE; TRICHOSPORON; URTICARIA; ZYGOMYCETES; ZYGOMYCOSIS;

EID: 84993804217     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620711410098     Document Type: Review

References (142)

1. Ahmad S.R. Singer S.J. Leissa B.G. (2001) Congestive heart failure associated with itraconazole. Lancet 357: 1766–1767.
2. Al-Tanbal H. Al Humaidan H. Al-Nounou R. Roberts G. Tesfamichael K. Owaidah T. (2010) The value and practicality of granulocyte transfusion: a single oncology centre experience. Transfus Med 20: 160–168.
3. Anaissie E.J. (2008) Diagnosis and therapy of fungal infection in patients with leukemia–new drugs and immunotherapy. Best Pract Res Clin Haematol 21: 683–690.
4. Anaissie E.J. Rex J.H. Uzun O. Vartivarian S. (1998) Predictors of adverse outcome in cancer patients with candidemia. Am J Med 104: 238–245.
5. Ang A.L. Linn Y.C. (2010) Treatment of severe neutropenic sepsis with granulocyte transfusion in the current era - experience from an adult haematology unit in Singapore. Transfus Med in press.
6. Armstrong-James D. Teo I.A. Shrivastava S. Petrou M.A. Taube D. Dorling A. et al (2010) Exogenous interferon-gamma immunotherapy for invasive fungal infections in kidney transplant patients. Am J Transplant 10: 1796–1803.
7. Ascioglu S. Rex J.H. de Pauw B. Bennett J.E. Bille J. Crokaert F. et al (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34: 7–14.
8. Auberger J. Lass-Florl C. Ulmer H. Nogler-Semenitz E. Clausen J. Gunsilius E. et al (2008) Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol 88: 508–515.
9. Baddley J.W. Andes D.R. Marr K.A. Kontoyiannis D.P. Alexander B.D. Kauffman C.A. et al (2010) Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis 50: 1559–1567.
10. Berenguer J. Buck M. Witebsky F. Stock F. Pizzo P.A. Walsh T.J. (1993) Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis 17: 103–109.
11. Betts R. Glasmacher A. Maertens J. Maschmeyer G. Vazquez J.A. Teppler H. et al (2006) Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer 106: 466–473.
12. Bodey G.P. Mardani M. Hanna H.A. Boktour M. Abbas J. Girgawy E. et al (2002) The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 112: 380–385.
13. Bow E.J. (2008) Considerations in the approach to invasive fungal infection in patients with haematological malignancies. Br J Haematol 140: 133–152.
14. Burgos A. Zaoutis T.E. Dvorak C.C. Hoffman J.A. Knapp K.M. Nania J.J. et al (2008) Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics 121: e1286–e1294.
15. Caillot D. Casasnovas O. Bernard A. Couaillier J.F. Durand C. Cuisenier B. et al (1997) Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 15: 139–147.
16. Caillot D. Couaillier J.F. Bernard A. Casasnovas O. Denning D.W. Mannone L. et al (2001) Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 19: 253–259.
17. Chamilos G. Lewis R.E. Kontoyiannis D.P. (2008) Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 47: 503–509.
18. Chamilos G. Luna M. Lewis R.E. Bodey G.P. Chemaly R. Tarrand J.J. et al (2006) Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica 91: 986–989.
19. Chamilos G. Marom E.M. Lewis R.E. Lionakis M.S. Kontoyiannis D.P. (2005) Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 41: 60–66.
20. Chanock S.J. Toltzis P. Wilson C. (1993) Cross-reactivity between Stomatococcus mucilaginosus and latex agglutination for cryptococcal antigen. Lancet 342: 1119–1120.
21. Chen S. Slavin M. Nguyen Q. Marriott D. Playford E.G. Ellis D. et al (2006) Active surveillance for candidemia, Australia. Emerg Infect Dis 12: 1508–1516.
22. Cordonnier C. Pautas C. Maury S. Vekhoff A. Farhat H. Suarez F. et al (2009) Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 48: 1042–1051.
23. Cordonnier C. Schwarzinger M. (2009) Reply to Marr et al. Clin Infect Dis 49: 1139–1140.
24. Dadachova E. Howell R.W. Bryan R.A. Frenkel A. Nosanchuk J.D. Casadevall A. (2004) Susceptibility of the human pathogenic fungi Cryptococcus neoformans and Histoplasma capsulatum to gamma-radiation versus radioimmunotherapy with alpha- and beta-emitting radioisotopes. J Nucl Med 45: 313–320.
25. Dasbach E.J. Davies G.M. Teutsch S.M. (2000) Burden of aspergillosis-related hospitalizations in the United States. Clin Infect Dis 31: 1524–1528.
26. Denning D.W. Griffiths C.E. (2001) Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol 26: 648–653.
27. Denning D.W. Marinus A. Cohen J. Spence D. Herbrecht R. Pagano L. et al (1998) An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect 37: 173–180.
28. Dodds Ashley E.S. Lewis R. Lewis James S. Martin C. Andes D. (2006) Pharmacology of Systemic Antifungal Agents. Clin Infect Dis 43(Suppl. 1): S28–S39.
29. Donnelly J.P. (2006) Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a ways to go. Clin Infect Dis 42: 487–489.
30. Einsele H. Loeffler J. (2008) Contribution of new diagnostic approaches to antifungal treatment plans in high-risk haematology patients. Clin Microbiol Infect 14(Suppl. 4): 37–45.
31. Engler H.D. Shea Y.R. (1994) Effect of potential interference factors on performance of enzyme immunoassay and latex agglutination assay for cryptococcal antigen. J Clin Microbiol 32: 2307–2308.
32. Garey K.W. Rege M. Pai M.P. Mingo D.E. Suda K.J. Turpin R.S. et al (2006) Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43: 25–31.
33. Goldberg E. Gafter-Gvili A. Robenshtok E. Leibovici L. Paul M. (2008) Empirical antifungal therapy for patients with neutropenia and persistent fever: Systematic review and meta-analysis. Eur J Cancer 44: 2192–2203.
34. Greenberg R.N. Mullane K. van Burik J.A. Raad I. Abzug M.J. Anstead G. et al (2006) Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 50: 126–133.
35. Greene R.E. Schlamm H.T. Oestmann J.W. Stark P. Durand C. Lortholary O. et al (2007) Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 44: 373–379.
36. Groll A.H. Giri N. Petraitis V. Petraitiene R. Candelario M. Bacher J.S. et al (2000) Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 182: 274–282.
37. Groll A.H. Lyman C.A. Petraitis V. Petraitiene R. Armstrong D. Mickiene D. et al (2006) Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob Agents Chemother 50: 3418–3423.
38. Groll A.H. Piscitelli S.C. Walsh T.J. (1998) Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 44: 343–500.
39. Hachem R. Hanna H. Kontoyiannis D. Jiang Y. Raad I. (2008 a) The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 112: 2493–2499.
40. Hachem R. Sumoza D. Hanna H. Girgawy E. Munsell M. Raad I. (2006) Clinical and radiologic predictors of invasive pulmonary aspergillosis in cancer patients: should the European Organization for Research and Treatment of Cancer / Mycosis Study Group (EORTC/MSG) criteria be revised? Cancer 106: 1581–1586.
41. Hachem R.Y. Boktour M.R. Hanna H.A. Husni R.N. Torres H.A. Afif C. et al (2008 b) Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. Cancer 112: 1282–1287.
42. Hahn-Ast C. Glasmacher A. Muckter S. Schmitz A. Kraemer A. Marklein G. et al (2010) Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006. J Antimicrob Chemother 65: 761–768.
43. Hammond S.P. Marty F.M. Bryar J.M. de Angelo D.J. Baden L.R. (2010) Invasive fungal disease in patients treated for newly diagnosed acute leukemia. Am J Hematol 85: 695–699.
44. Hayden R.T. Isotalo P.A. Parrett T. Wolk D.M. Qian X. Roberts G.D. et al (2003) In situ hybridization for the differentiation of Aspergillus, Fusarium, and Pseudallescheria species in tissue section. Diagn Mol Pathol 12: 21–26.
45. Herbrecht R. Denning D.W. Patterson T.F. Bennett J.E. Greene R.E. Oestmann J.W. et al (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347: 408–415.
46. Horn D.L. Ostrosky-Zeichner L. Morris M.I. Ullmann A.J. Wu C. Buell D.N. et al (2010) Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials. Eur J Clin Microbiol Infect Dis 29: 223–229.
47. Hughes W.T. Armstrong D. Bodey G.P. Bow E.J. Brown A.E. Calandra T. et al (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34: 730–751.
48. Imhof A. Balajee S.A. Fredricks D.N. Englund J.A. Marr K.A. (2004) Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 39: 743–746.
49. Kaufman L. Standard P.G. Jalbert M. Kraft D.E. (1997) Immunohistologic identification of Aspergillus spp. and other hyaline fungi by using polyclonal fluorescent antibodies. J Clin Microbiol 35: 2206–2209.
50. Kim D.H. Sohn S.K. Kim J.G. Suh J.S. Lee K.S. Lee K.B. (2004) Clinical impact of hyperacute graft-versus-host disease on results of allogeneic stem cell transplantation. Bone Marrow Transplant 33: 1025–1030.
51. Klastersky J. (2004) Antifungal therapy in patients with fever and neutropenia–more rational and less empirical? N Engl J Med 351: 1445–1447.
52. Kontoyiannis D.P. Chamilos G. Lewis R.E. Giralt S. Cortes J. Raad I.I. et al (2007) Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 110: 1303–1306.
53. Kontoyiannis D.P. Lionakis M.S. Lewis R.E. Chamilos G. Healy M. Perego C. et al (2005) Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 191: 1350–1360.
54. Kontoyiannis D.P. Vaziri I. Hanna H.A. Boktour M. Thornby J. Hachem R. et al (2001) Risk Factors for Candida tropicalis fungemia in patients with cancer. Clin Infect Dis 33: 1676–1681.
55. Koo S. Bryar J.M. Page J.H. Baden L.R. Marty F.M. (2009) Diagnostic performance of the (1–>3)-beta-D-glucan assay for invasive fungal disease. Clin Infect Dis 49: 1650–1659.
56. Labelle A.J. Micek S.T. Roubinian N. Kollef M.H. (2008) Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 36: 2967–2972.
57. Lamaris G.A. Lewis R.E. Chamilos G. May G.S. Safdar A. Walsh T.J. et al (2008) Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis 198: 186–192.
58. Laniado-Laborin R. Cabrales-Vargas M.N. (2009) Amphotericin B: side effects and toxicity. Rev Iberoam Micol 26: 223–227.
59. Lass-Florl C. Aigner J. Gunsilius E. Petzer A. Nachbaur D. Gastl G. et al (2001) Screening for Aspergillus spp. using polymerase chain reaction of whole blood samples from patients with haematological malignancies. Br J Haematol 113: 180–184.
60. Lass-Florl C. Resch G. Nachbaur D. Mayr A. Gastl G. Auberger J. et al (2007) The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 45: e101–e104.
61. Lecciones J.A. Lee J.W. Navarro E.E. Witebsky F.G. Marshall D. Steinberg S.M. et al (1992) Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis 14: 875–883.
62. Lee F.Y. Mossad S.B. Adal K.A. (1999) Pulmonary mucormycosis: the last 30 years. Arch Intern Med 159: 1301–1309.
63. Leon C. Ruiz-Santana S. Saavedra P. Almirante B. Nolla-Salas J. Alvarez-Lerma F. et al (2006) A bedside scoring system (Candida score) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 34: 730–737.
64. Leventakos K. Lewis R.E. Kontoyiannis D.P. (2010) Fungal infections in leukemia patients: how do we prevent and treat them? Clin Infect Dis 50: 405–415.
65. Lewis R.E. Liao G. Hou J. Chamilos G. Prince R.A. Kontoyiannis D.P. (2007) Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 51: 1253–1258.
66. Lin L. Ibrahim A.S. Baquir B. Fu Y. Applebaum D. Schwartz J. et al (2010) Safety and efficacy of activated transfected killer cells for neutropenic fungal infections. J Infect Dis 201: 1708–1717.
67. Maertens J. (2007) Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies. Eur J Haematol 78: 275–282.
68. Maertens J. Theunissen K. Verhoef G. Verschakelen J. Lagrou K. Verbeken E. et al (2005) Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41: 1242–1250.
69. Maertens J. Verhaegen J. Demuynck H. Brock P. Verhoef G. Vandenberghe P. et al (1999) Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis. J Clin Microbiol 37: 3223–3228.
70. Maertens J. Verhaegen J. Lagrou K. van Eldere J. Boogaerts M. (2001) Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 97 (6): 1604–1610.
71. Marr K.A. (2010) Fungal infections in oncology patients: update on epidemiology, prevention, and treatment. Curr Opin Oncol 22: 138–142.
72. Marr K.A. Balajee S.A. McLaughlin L. Tabouret M. Bentsen C. Walsh T.J. (2004) Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 190: 641–649.
73. Marr K.A. Laverdiere M. Gugel A. Leisenring W. (2005) Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 40: 1762–1769.
74. Marr K.A. Leisenring W. Bow E. (2009) Empirical versus preemptive antifungal therapy for fever during neutropenia. Clin Infect Dis 49: 1138–1139. author reply 1139-1140.
75. Martin G.S. Mannino D.M. Eaton S. Moss M. (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348: 1546–1554.
76. Marty F.M. Cosimi L.A. Baden L.R. (2004) Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 350: 950–952.
77. Marty F.M. Lowry C.M. Lempitski S.J. Kubiak D.W. Finkelman M.A. Baden L.R. (2006) Reactivity of (1–>3)-beta-d-glucan assay with commonly used intravenous antimicrobials. Antimicrob Agents Chemother 50: 3450–3453.
78. Matt P. Bernet F. Habicht J. Gambazzi F. Gratwohl A. Zerkowski H.R. et al (2004) Predicting outcome after lung resection for invasive pulmonary aspergillosis in patients with neutropenia. Chest 126: 1783–1788.
79. McLintock L.A. Jordanides N.E. Allan E.K. Copland M. Stewart K. Parker A. et al (2004) The use of a risk group stratification in the management of invasive fungal infection: a prospective validation. Br J Haematol 124: 403–404.
80. McMullan R. Metwally L. Coyle P.V. Hedderwick S. McCloskey B. O'Neill H.J. et al (2008) A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults. Clin Infect Dis 46: 890–896.
81. Meersseman W. Lagrou K. Maertens J. Wilmer A. Hermans G. Vanderschueren S. et al (2008) Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 177: 27–34.
82. Mennink-Kersten M.A. Donnelly J.P. Verweij P.E. (2004) Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 4: 349–357.
83. Mennink-Kersten M.A. Ruegebrink D. Verweij P.E. (2008) Pseudomonas aeruginosa as a cause of 1,3-beta-D-glucan assay reactivity. Clin Infect Dis 46: 1930–1931.
84. Morgan J. Meltzer M.I. Plikaytis B.D. Sofair A.N. Huie-White S. Wilcox S. et al (2005) Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 26: 540–547.
85. Morrell M. Fraser V.J. Kollef M.H. (2005) Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49: 3640–3645.
86. Mousset S. Hermann S. Klein S.A. Bialleck H. Duchscherer M. Bomke B. et al (2005) Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann Hematol 84: 734–741.
87. Muhlemann K. Wenger C. Zenhausern R. Tauber M.G. (2005) Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia 19: 545–550.
88. Nakase K. Tsuji K. Miyanishi E. Shirakawa S. (1990) Pathogenesis of fever of unknown origin in patients with acute leukemia and granulocytopenia. Med Hypotheses 33: 235–237.
89. Nguyen M.H. Leather H. Clancy C.J. Cline C. Jantz M.A. Kulkarni V. et al (2010) Galactomannan Testing in Bronchoalveolar Lavage Fluid Facilitates the Diagnosis of Invasive Pulmonary Aspergillosis in Patients with Hematologic Malignancies and Stem Cell Transplant Recipients. Biol Blood Marrow Transplant in press.
90. Nivoix Y. Velten M. Letscher-Bru V. Moghaddam A. Natarajan-Ame S. Fohrer C. et al (2008) Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 47: 1176–1184.
91. O'Grady N.P. Barie P.S. Bartlett J.G. Bleck T. Garvey G. Jacobi J. et al (1998) Practice guidelines for evaluating new fever in critically ill adult patients. Task Force of the Society of Critical Care Medicine and the Infectious Diseases Society of America. Clin Infect Dis 26: 1042–1059.
92. Obayashi T. Negishi K. Suzuki T. Funata N. (2008) Reappraisal of the serum (1–>3)-beta-D-glucan assay for the diagnosis of invasive fungal infections–a study based on autopsy cases from 6 years. Clin Infect Dis 46: 1864–1870.
93. Ostrosky-Zeichner L. Casadevall A. Galgiani J.N. Odds F.C. Rex J.H. (2010) An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov 9: 719–727.
94. Ostrosky-Zeichner L. Sable C. Sobel J. Alexander B.D. Donowitz G. Kan V. et al (2007) Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 26: 271–276.
95. Pachl J. Svoboda P. Jacobs F. Vandewoude K. van der Hoven B. Spronk P. et al (2006) A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 42: 1404–1413.
96. Pagano L. Caira M. Candoni A. Offidani M. Fianchi L. Martino B. et al (2006) The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91: 1068–1075.
97. Pagano L. Caira M. Candoni A. Offidani M. Martino B. Specchia G. et al (2010) Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 95: 644–650.
98. Pagano L. Offidani M. Fianchi L. Nosari A. Candoni A. Piccardi M. et al (2004) Mucormycosis in hematologic patients. Haematologica 89: 207–214.
99. Pappas P.G. Kauffman C.A. Andes D. Benjamin D.K. Jr. Calandra T.F. Edwards J.E. Jr. et al (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48: 503–535.
100. Pappas P.G. Kauffman C.A. Perfect J. Johnson P.C. McKinsey D.S. Bamberger D.M. et al (1995) Alopecia associated with fluconazole therapy. Ann Intern Med 123: 354–357.
101. Pascual A. Calandra T. Bolay S. Buclin T. Bille J. Marchetti O. (2008) Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 46: 201–211.
102. Patterson T.F. (2009) Risk stratification for invasive aspergillosis: early assessment of host susceptibility. Med Mycol 47(Suppl. 1): S255–S260.
103. Pazos C. Ponton J. Del Palacio A. (2005) Contribution of (1->3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 43: 299–305.
104. Pfaller M.A. Pappas P.G. Wingard J.R. (2006) Invasive Fungal Pathogens: Current Epidemiological Trends. Clin Infect Dis 43(Suppl. 1): S3–S14.
105. Pfeiffer C.D. Fine J.P. Safdar N. (2006) Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 42: 1417–1727.
106. Pickering J.W. Sant H.W. Bowles C.A. Roberts W.L. Woods G.L. (2005) Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 43: 5957–5962.
107. Prentice H.G. Kibbler C.C. Prentice A.G. (2000) Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 110: 273–284.
108. Purkins L. Wood N. Greenhalgh K. Allen M.J. Oliver S.D. (2003) Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 56(Suppl. 1): 10–16.
109. Reed C. Bryant R. Ibrahim A.S. Edwards J. Jr Filler S.G. Goldberg R. et al (2008) Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 47: 364–371.
110. Roden M.M. Nelson L.D. Knudsen T.A. Jarosinski P.F. Starling J.M. Shiflett S.E. et al (2003) Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics. Clin Infect Dis 36: 1213–1220.
111. Roden M.M. Zaoutis T.E. Buchanan W.L. Knudsen T.A. Sarkisova T.A. Schaufele R.L. et al (2005) Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 41: 634–653.
112. Ruping M.J. Heinz W.J. Kindo A.J. Rickerts V. Lass-Florl C. Beisel C. et al (2010) Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother 65: 296–302.
113. Ruping M.J. Vehreschild J.J. Cornely O.A. (2008) Patients at high risk of invasive fungal infections: when and how to treat. Drugs 68: 1941–1962.
114. Segal B.H. Almyroudis N.G. Battiwalla M. Herbrecht R. Perfect J.R. Walsh T.J. et al (2007) Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 44: 402–409.
115. Senn L. Robinson J.O. Schmidt S. Knaup M. Asahi N. Satomura S. et al (2008) 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 46: 878–885.
116. Sharkey P.K. Rinaldi M.G. Dunn J.F. Hardin T.C. Fetchick R.J. Graybill J.R. (1991) High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother 35: 707–713.
117. Singh N. (2001) Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 33: 1692–1696.
118. Singh N. Aguado J.M. Bonatti H. Forrest G. Gupta K.L. Safdar N. et al (2009) Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis 200: 1002–1011.
119. Siwek G.T. Dodgson K.J. de Magalhaes-Silverman M. Bartelt L.A. Kilborn S.B. Hoth P.L. et al (2004) Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 39: 584–587.
120. Spellberg B. Ibrahim A. (2010) Recent Advances in the Treatment of Mucormycosis. Curr Infect Dis Rep 12: 423–429.
121. Spellberg B. Walsh T.J. Kontoyiannis D.P. Edwards J. Jr Ibrahim A.S. (2009) Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 48: 1743–1751.
122. Spellberg B.J. Collins M. French S.W. Edwards J.E. Jr Fu Y. Ibrahim A.S. (2005 a) A phagocytic cell line markedly improves survival of infected neutropenic mice. J Leukoc Biol 78: 338–344.
123. Spellberg B.J. Ibrahim A.S. Avenissian V. Filler S.G. Myers C.L. Fu Y. et al (2005 b) The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice. Infect Immun 73: 6191–6193.
124. Sung L. Gamis A. Alonzo T.A. Buxton A. Britton K. Deswarte-Wallace J. et al (2009) Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia. Cancer 115: 1100–1108.
125. Taur Y. Cohen N. Dubnow S. Paskovaty A. Seo S.K. (2010) Effect of antifungal therapy timing on mortality in cancer patients with candidemia. Antimicrob Agents Chemother 54: 184–190.
126. Torres H.A. Rivero G.A. Lewis R.E. Hachem R. Raad I.I. Kontoyiannis D.P. (2003) Aspergillosis caused by non-fumigatus Aspergillus species: risk factors and in vitro susceptibility compared with Aspergillus fumigatus. Diagn Microbiol Infect Dis 46: 25–28.
127. Uzun O. Anaissie E.J. (2000) Predictors of outcome in cancer patients with candidemia. Ann Oncol 11: 1517–1521.
128. van Burik J.A. Hare R.S. Solomon H.F. Corrado M.L. Kontoyiannis D.P. (2006) Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 42: e61–e65.
129. van de Veerdonk F.L. Netea M.G. Joosten L.A. van der Meer J.W. Kullberg B.J. (2010) Novel strategies for the prevention and treatment of Candida infections: the potential of immunotherapy. FEMS Microbiol Rev in press.
130. Vandewoude K. Vogelaers D. Decruyenaere J. Jaqmin P. de Beule K. van Peer A. et al (1997) Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. Antimicrob Agents Chemother 41: 2714–2718.
131. Vazquez Jose A. Sobel Jack D. (2006) Reviews of anti‐infective agents: anidulafungin: a novel echinocandin. Clin Infect Dis 43: 215–222.
132. Verweij P.E. Poulain D. Obayashi T. Patterson T.F. Denning D.W. Ponton J. (1998) Current trends in the detection of antigenaemia, metabolites and cell wall markers for the diagnosis and therapeutic monitoring of fungal infections. Med Mycol 36(Suppl. 1): 146–155.
133. Verweij P.E. van Die L. Donnelly J.P. (2007) Halo sign and improved outcome. Clin Infect Dis 44: 1666–1667. author reply 1667-1668.
134. von Eiff M. Roos N. Schulten R. Hesse M. Zuhlsdorf M. van de Loo J. (1995) Pulmonary aspergillosis: early diagnosis improves survival. Respiration 62: 341–347.
135. Wahba H. Truong M.T. Lei X. Kontoyiannis D.P. Marom E.M. (2008) Reversed halo sign in invasive pulmonary fungal infections. Clin Infect Dis 46: 1733–1737.
136. Walsh T.J. Anaissie E.J. Denning D.W. Herbrecht R. Kontoyiannis D.P. Marr K.A. et al (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46: 327–360.
137. Walsh T.J. Chanock S.J. (1998) Diagnosis of invasive fungal infections: advances in nonculture systems. Curr Clin Top Infect Dis 18: 101–153.
138. Walsh T.J. Kontoyiannis D.P. (2008) Editorial commentary: what is the role of combination therapy in management of zygomycosis? Clin Infect Dis 47: 372–374.
139. Walsh T.J. Melcher G.P. Lee J.W. Pizzo P.A. (1993) Infections due to Trichosporon species: new concepts in mycology, pathogenesis, diagnosis and treatment. Curr Top Med Mycol 5: 79–113.
140. Weiser M.A. Cabanillas M.E. Konopleva M. Thomas D.A. Pierce S.A. Escalante C.P. et al (2004) Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer 100: 1179–1185.
141. Wheeler R.T. Fink G.R. (2006) A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog 2: e35–e35.
142. Wiederhold N.P. Lewis R.E. Kontoyiannis D.P. (2003) Invasive aspergillosis in patients with hematologic malignancies. Pharmacotherapy 23: 1592–1610.